Ziopharm Oncology to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference
September 25 2018 - 7:30AM
Ziopharm Oncology, Inc. (Nasdaq:ZIOP), today announced that
Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present
at the Cantor Fitzgerald 2018 Global Healthcare Conference in New
York on Tuesday, Oct. 2, at 2:15 p.m. ET.
To access a live audio webcast of the
presentation, please visit the Investor Relations section at
www.ziopharm.com. The webcast will be archived for 90 days.
About Ziopharm Oncology, Inc.
Ziopharm Oncology is a Boston-based
biotechnology company focused on the development of next-generation
immunotherapies utilizing gene- and cell-based therapies to treat
patients with cancer. In partnership with Precigen Inc., a
wholly-owned subsidiary of Intrexon Corporation (NYSE:XON),
Ziopharm is focused on the development of two platform technologies
designed to deliver safe, effective and scalable cell- and
viral-based therapies for the treatment of multiple cancer types:
Controlled IL-12 and Sleeping Beauty for genetically
modifying T cells. The Company's lead asset, Ad-RTS-hIL-12 plus
veledimex, has demonstrated in clinical trials the potential to
control interleukin-12, leading to an infiltration of T cells that
fight cancer. Ad-RTS-hIL-12 plus veledimex is being evaluated as a
monotherapy and in combination with immune checkpoint inhibitors to
treat brain cancer and other tumor types. The Company also is
advancing therapies using Sleeping Beauty, a non-viral
approach to genetically modify chimeric antigen receptor (CAR+) and
T-cell receptor (TCR+) T cells, which target specific antigens in
blood cancers and neoantigens in solid tumors. Sleeping
Beauty is designed using the Company's point-of-care
technology, a shortened manufacturing process which potentially can
be developed as a decentralized manufacturing process based in
hospitals. These programs are being advanced in collaboration with
Precigen and with MD Anderson Cancer Center, the National Cancer
Institute and Merck KGaA, Darmstadt, Germany.
Forward-Looking Statements
Disclaimer
This press release contains certain
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical
facts, and in some cases can be identified by terms such as "may,"
"will," "could," "expects," "plans," "anticipates," and "believes."
All such statements are subject to certain risks and uncertainties,
many of which are difficult to predict and generally beyond the
control of the Company, that could cause actual results to differ
materially from those expressed in, or implied by, the
forward-looking statements. These risks and uncertainties include,
but are not limited to: the Company’s ability to advance certain
activities; whether chimeric antigen receptor T cell (CAR-T)
approaches, Ad-RTS-hIL-12, TCR and NK cell-based therapies, or any
other product candidates will advance further in the preclinical
research or clinical trial process and whether and when, if at all,
they will receive final approval from the U.S. Food and Drug
Administration or equivalent foreign regulatory agencies and for
which indications; whether chimeric antigen receptor T cell (CAR-T)
approaches, Ad-RTS-hIL-12, TCR and NK cell-based therapies, and the
Company's other therapeutic products it develops will be
successfully marketed if approved; the strength and enforceability
of the Company's intellectual property rights; competition from
other pharmaceutical and biotechnology companies; as well as other
risk factors contained in the Company's periodic and interim
reports filed from time to time with the Securities and Exchange
Commission, including but not limited to, the risks and
uncertainties set forth in the "Risk Factors" section of the
Company's Annual Report on Form 10-K for the fiscal year
ended December 31, 2017 and subsequent reports that the
Company may file with the Securities and Exchange Commission.
Readers are cautioned not to place undue reliance on these
forward-looking statements that speak only as of the date hereof,
and the Company does not undertake any obligation to revise and
disseminate forward-looking statements to reflect events or
circumstances after the date hereof, or to reflect the occurrence
of or non-occurrence of any events.
Contact: David Connolly Ziopharm Oncology 617-502-1881
dconnolly@ziopharm.com
Intrexon (NASDAQ:XON)
Historical Stock Chart
From Mar 2024 to Apr 2024
Intrexon (NASDAQ:XON)
Historical Stock Chart
From Apr 2023 to Apr 2024